Agenda Update: See you in Chengdu on 2026BPD Month 11-5! Grab your free meal vouchers now.

2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityGrandly hosted by Echemi Medical, co-organized by Kelun-Biotech, with innovative partnerships from Jingze Bio, Haiboer Pharma, Zhishan Weixin, and Weijin Bio. The event will bring together2000+Professional Buyers,70+Keynote Speakers, Built for ImpactTech Forum, Full-Chain Exhibition, BPD Match, Closed-Door MeetingThrough diverse sessions centered on technical reports and case studies, we facilitate CMC professional exchange, empower emerging CMC talent, and build an efficient platform focused on deep expertise and practical problem-solving for the industry.Major agenda update! Get the latest schedule in one quick read.

2026BPD Latest Chengdu Forum Agenda

Schedule updated through 10/13

Opening Forum

Industrial Ecosystem and Full Process Chain

Interview: Source Innovation and Global Competition: A New Paradigm and Cycle for Chinese Innovative Drug Companies

Moderator: Li Kechun, Partner at Yuan Sheng Capital

Guest: Xiang Yu, CEO of Boryao Biologics

Interview: CMC and Manufacturing Capacity in the Global Expansion Era – From Technology Transfer to Global Supply

Guest: Li Shude, former Chief Manufacturing Officer at China Resources Biology

Biologics Process Development and Quality Control Forum

Innovative Development of Upstream Biopharmaceutical Processes

Report: Design of Multifunctional Fusion Proteins and CMC Development Strategies

Guest: Wang Zhenyu, Senior Director, GEMCare

Report: Cutting-Edge Strategies for Developing High-Yield Cell Lines for Complex Molecules

Guest: Zhang Yu, Vice Director of Process Development, Sanjiu Guojian

Report: Process Feasibility Direction for Early Research Projects

Speaker: Zhao Yanyan, Senior Director of Process Development Center, Bo-Ant Biopharma

Report: ADC Process Development Direction

Guest: Dong Fusheng, Operations Director, Chongqing Haoyuan

Innovation Development of Downstream Biopharmaceutical Processes

Report: Design and Process Development of Fusion Proteins

Guest: Huang Haiqiu, Vice Dean and Director of R&D, Jeku Biotech

Report: Strengthening Downstream Processing Technologies: Applications of Membrane Chromatography in Antibody Purification

Guest: Zhao Puya, Head of Downstream Technology at Cayman Biopharm

Report: Challenges and Strategies in Complex Antibody Purification Processes

Guest: Zhu Ying, Head of Downstream Process, Zhenge Biotechnology

Masterclass

Report: Contamination Control Strategy for Biologics and Inspection Deficiencies

Guest: Hongyu Tan, a senior domestic pharmaceutical GMP expert and former core inspector at CFDI.

ADC Manufacturing Process and Quality Control

Report: Comparative Study of ADC

Guest: Qu Yaocheng, Vice Director of Quality Control Department, Sinopharm Crosslink

Report: Key Considerations for ADC Special Quality Control Strategies, Hardware Facilities, and Workshop Layout (Draft)

Guest: Professor Park, former head of the Drug GMP Inspection Team at the National Medical Products Administration

Report: Iterative CMC Strategy Overcomes Scale-Up Challenges for Next-Generation Conjugate Drugs

Guest: Hongbin Song, Senior Director of ADC CMC at Innovent Biologics

Report: Quality Research and Control Strategy for XDC Drugs

Guest: Xu Ying,皓元医药 (Hao Yuan Pharmaceutical), Director / Head of ARD

Report: Analytical Characterization Challenges for Complex Molecules (ADCs, Bispecific Antibodies, and Fusion Proteins)

Guest: Mingze Sun, CMC Director at Tian Guangshi Biotech

Report: Key Points on GMP Manufacturing and On-site Inspection of ADCs

CGT R&D and Process Quality Control Forum

Innovative Complex Molecule Drug Development Forum

High-level Strategy

Interview: Differentiated Design, Clinical Strategy, and Strategic Decision-Making for Next-Generation Molecules

Guest: Chen Su, General Manager of Chengdu Weijin Biotechnology

Gu Haihua, Senior Vice President of R&D at Fosun Kary

In Vivo Delivery Strategies and Development Progress

Considerations for In Vivo CAR-T Therapy Development

Guest: Gu Haihua, Senior Vice President of R&D at Fosun Kerry

Report: Development of In Vivo LNP Delivery Systems

Guest: Gu Yongjun, Wiszen Biotech, Partner & Head of CMC and Intellectual Property

Report: In Vivo CAR-M Development

Guest: Zhang Shaolong, R&D Director, Saiyuan Bio

Innovative R&D and Scalable Production of Peptide Drugs

Report: CR059: Long-acting Efficacy Study of Circular RNA Encoding GLP-1 Analog

Guest: Peiya, Chief Director of Early Drug R&D at PegBio

Report: Engineering of Metabolic Peptides

Guest: Nie Yunyu, Chief Scientist of Metabolic Peptide Engineering at Innovent Biologics

Report: Natural Peptide Library & AI Discovery Platform

Guest: Liu Lulu, BD Director, PedBio

Report: Formulation Development Direction (Tentative)

Speaker: Yang Fengyun, Director of Formulation Development, Gansun Pharmaceutical

Report: Super-Scale Production of GLP-1 Class Peptide Drugs (Provisional)

Guest: Liu Hedong, Senior Manager of Microbial Process Development Platform & Hengqin Early Development Platform, Federal Biotech

Interview: CMC and Industrialization of Peptide Drugs: Scale-up, Quality Control, and Global Compliance

Guest: Fan Jun, Vice President of CMC R&D Center, MacroCap

Innovative Development of Nucleic Acid Drugs and Extracellular Delivery Innovations

Report: From COVID-19 to Oncology – Paradigm Shift in mRNA Therapy Commercialization

Guest: Li Weimin, President of Preclinical R&D at Abogen

Report: Dual-Target siRNA Drug

Guest: Wan Jinqiao, Chairman of Xianyan Biomaterials

Report: From Identification to Delivery: Application of Nucleic Acid Aptamers in Extracellular Targeted Delivery

Guest: Luo Zhaofeng, Senior Engineer at the Hangzhou Institute of Medicine, Chinese Academy of Sciences; Deputy Director and Co-founder of the Nucleic Acid Aptamer Screening Center

Report: Novel Lipid Nanoparticle Nucleic Acid Delivery System

Guest: Li Jianguang, Haichang Biopharma, CSO

AI for Pharmaceuticals

AI In Drug Discovery

Report: Generative AI-Driven Antibody De Novo Design

Guest: Wang Tianyuan, CEO of Combiotech

Report: AI-Driven Drug Discovery and Clinical Translation

Guest: Zhang Liang, Researcher at the Institute of Health Sciences, Chinese Academy of Sciences, Hangzhou

Report: AI Data Security in Biopharmaceutical Enterprises: From Knowledge Retrieval to Agent Execution

Guest: Liu Qihé, TransBio, Head of AI Development

Report: Intelligent Automation Discovery Platform – Differentiated Discovery Strategies for Next-Generation ADC/XDC Drugs

Guest: Zhang Hongwei, Chief Information Officer and Managing Director of Beijing at Kede Pharma

Regulatory Compliance & Production Forum

AI for Pharmaceuticals

Regulations and On-site Verification

Report: Scientific Oversight, Innovation-Driven Drug Development

Guest: Ran Zhang, Beihe Kangcheng, Chief Regulatory Advisor

Report: IND Strategy for Simultaneous Submission in China and the United States

Guest: Lei Juan, Registration Director, Hansi Aite

Report: Driving Research Through Regulation — Key Points for Clinical Evaluation in New Drug Marketing Applications

Guest: Chen Yangqi, Chengdu Xuyuan Biology, COO

Report: Differences in Pharmaceutical Registration Submissions and CMC Regulation Between China and Other Countries

Commercialization of Biologics Manufacturing

Report: Segmented Contract Manufacturing of Biological Products (Provisional)

Guest: He Yanchao, Simcere Pharmaceutical Group, Head of Quality/Qualified Person

Report: Key Success Factors for Technology Transfer (Provisional)

Guest: Li Hongcheng, Director of Upstream Process Development, Sinopharm Jinke

Report: Key Elements and Best Practices for Pre-Market Commercial Manufacturing in Biopharmaceuticals

Guest: Yang Shiming, Director of Production, Chubb Bio

Report: Mass Production Reshapes the Global Bio-Manufacturing Landscape

Guest: Biotree Biopharmaceuticals

Masterclass

Report: Planning, Building, and Outstanding Operations of a Smart Biopharma Manufacturing Facility

Guest: Li Shude, former Chief Manufacturing Officer at China Resources Biology

AI-Enabled CMC Development for Biopharmaceuticals

Report: Study on AI Digitalization, Compliance, and Business Impact

Guest: Ma Jun, former Vice President of Junshi Biosciences

Report: AI-Enabled Biopharmaceutical CMC and Regulatory Considerations

Guest: Dongqiang Lin, Zhejiang University, Professor

Report: Boundaries of AI Implementation in CMC Development

AI-Driven Commercial Biopharmaceutical Manufacturing

Report: Digital Transformation of Biopharmaceutical Manufacturing:

Henlius: Practices and Insights

Guest: Wei Gong, General Manager of ADC Development and Clinical Manufacturing at MacroGenics

Report: The Path and Practice of Digital Intelligence Advancement for Pharmaceutical Enterprises

Guest: Zhu Xiaofeng, Deputy General Manager of the Intelligent Data Department, China Resources Double Crane

Interview: Digital Intelligence Breakthrough and Efficiency Revolution in Commercial Production of Biologics

Guest: Zhang Hong, Senior Director of Digital Development Center for Human Drug Formulations, Qilu Pharmaceutical

Ma Jun, former Vice President at Junshi Biosciences

Dongqiang Lin, Zhejiang University, Professor

Forum on Innovative Development of Complex Molecular Drugs

CGT R&D and Process Quality Control Forum

Innovative R&D of Complex Molecules

Report: Development of Bispecific ADCs and Dual-Load ADCs

Report: Innovative ADC R&D (Tentative)

Guest: Zhenwei Miao, Chairman and CEO of Ake Rui Si & Ying Bai Rui

Report: Development of mRNA Tumor Vaccines

Report: Progress in KRAS Inhibitor Development

Guest: Li Yingfu, Founder & Chairman of Haibowei Pharmaceuticals

High-level Strategy

Interview: Industrial Breakthrough and Commercial Path Selection for the Full Nuclear Medicine Chain

Guest: Chen Dianjun, President and CSO of Chengdu Xingrui Jingxuan Biotechnology

Bai Ge, Guotong New Drugs, COO

Wang Zheng, CEO of Sinotrac Nuclear Medicine

Xiahai Hong, Chief Scientist at Guodian Tuhe Chuangxin (Chongqing) Technology Co., Ltd.

Innovative R&D and CMC Development Strategies for Radiopharmaceuticals

Report: The Critical Role of Novel Metal Chelators in Radiopharmaceutical Development

Guest: Wang Zheng, CEO of Sinotrac Nuclear Medicine

Report: Alpha Nuclide R&D and Production Direction

Guest: Xia Haihong, Chief Scientist, SPIC Nuclear Isotope Innovation (Chongqing) Technology Co., Ltd.

Innovative CGT Therapy Development

Report: Development and Progress of rAAV Gene Therapy for Aging-Related Diseases

Guest: Dong Biao, Founder of Zhishan Weixin

Report: Research and Application of Cidite Immunotherapy for Preventing Tumor Recurrence

Guest: Liu Dun, Vice President of Saide Biotech

Report: Progress in MSC-Based Liver Disease Therapy (Tentative)

Guest: Tan Yi, Vice President and Director of R&D at Qilu Cell Therapy

Report: Advances in Drug Research Derived from Pluripotent Stem Cells

Guest: Yan Xiang, Director of R&D, CloudTest Medicine

Innovative CGT Therapy Process Development and Scalable Manufacturing

Report: Key Points for CGT Manufacturing Inspection

Guest: Teacher Tu, Regulatory Expert

Platform: The World's First Dual-Plasmid Gene Therapy Drug Development Platform

Guest: Chen Lijing, COO/VP of Jinweike Bio

Report: Best Practices for Quality Control Standards of Clinical Extracellular Vesicles

Guest: Yang Shuangshuang, Research and Development Manager, Qilu Cell Therapy

Report: Closed Automated Stem Cell Production

Guest: Wu Shouliang, Deputy Director of Production Technology at Sino-Union

Interview: Process Scale-Up Strategies and Quality Control Challenges for CGT Products Under a Dual-Track System

Guest: Tan Binghe, Bonyo Bio, CTO

Yao Shuyuan

Chen Lijing, Kingway Biotech, COO/VP

Teacher Tu, Regulatory Expert

Hot Topics

Youth in Action

Interview: The Evolution of CMC Across Stages – From Technical Challenges to Commercial Success

Moderator: Tang Defang, Vice President of Jingze Bio

Guest: Ran Gugu, Salubris (Chengdu), Director of Project Management

Song Qingguo, Founder of Guanlan (Hong Kong) Medicine

Production and Verification

Report: Pending

Guest: Jiang Yu, Director of Formulation Production at Junshi Biosciences - Suzhou Zhonghe Biopharmaceutical Technology Co., Ltd.

Report: Quality System Resilience Behind Three FDA Inspections

Guest: Gang Cai, Huiyu Pharmaceutical, Group Quality Director

Discussion: Breaking Global Compliance Barriers for Biologics and Building End-to-End Capabilities

Small-Molecule Innovative Formulation Development and Manufacturing

Report: AI-Driven Small Molecule Formulation Design and Optimization

Report: Solubility Enhancement Strategies for Poorly Soluble Small Molecule Drugs

Report: Formulation Strategy for Modified New Drugs (Type 2 New Drug)

Report: Modernization of Formulations for Small-Molecule Active Components in Traditional Chinese Medicine

Report: Continuous Manufacturing and QbD for Small Molecule Formulations

Discussion: Ecosystem Gaps in Small-Molecule Innovation and Synergistic Pathways

Featured Event

Exclusive Lunch Event

CEO & CTO Closed-Door Meeting

Theme: AI Era – Strategic Planning and Critical Decisions for Western Pharmaceutical Companies (Executive Closed-Door Meeting)
Scale: 30 C-level executives and technical leaders from pharma/biotech companies

Focus: Strategic decisions for Western China pharmaceutical companies in AI drug development. No algorithmic showboating—only actionable insights. Designed for executives still planning their AI journey to clarify: whether to adopt, how to implement, where to allocate budget, and what pitfalls to avoid. Bridge the gap from "heard of it" to "ready to use."

• Report: How R&D Systems Are Being Rebuilt with AI: Redesigning Workflows and Decision Chains from Target to Candidate Molecule

• Report: How R&D Teams Leverage AI to Transform Knowledge Management and Cross-Functional Collaboration

• Discussion: From "Heard It" to "Thought It Through"—Three Critical Questions for AI Decision-Making